Loading...
Loading...
Karyopharm Therapeutics Inc.
, a clinical-stage pharmaceutical company, today announced the
presentation of data describing its oncology product candidates at the 26^th
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in
Barcelona, Spain held November 18 to 21, 2014. Data for its lead product
candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of
Nuclear Export / SINE™ compound, described its synergistic anti-tumor activity
in combination with DNA damage-inducing treatments such as anthracyclines or
radiation in a non-small cell lung cancer (NSCLC) mouse model. In addition, a
description of a newly developed pharmacodynamic assay designed to evaluate
direct Selinexor binding to XPO1 in patients was presented. Finally, data
describing the identification of novel mechanism PAK4 allosteric modulators
(PAMs) and their ability to inhibit tumor cell growth and induce apoptosis
were presented.
"Presentations on Karyopharm's oncology pipeline at the EORTC-NCI-AACR Annual
Meeting included data highlighting key Selinexor advantages, such as
synergistic activity in combination with DNA damaging agents and the
development of a new pharmcodynamic assay, as well as promising data on our
earlier-stage PAK4 program," said Sharon Shacham, PhD, MBA, President and
Chief Scientific Officer of Karyopharm. "Selinexor's synergy with DNA damaging
agents, such as anthracyclines and radiation in solid and hematological
cancers, provide the rationale for future combination clinical studies."
In a poster entitled "Selective Inhibitors of Nuclear Export (SINE™) Block the
Expression of DNA Damage Repair Proteins and Sensitize Cancer Cells to DNA
Damage Inducing Agents," data demonstrated that Selinexor inhibited the DNA
repair mechanisms in solid and hematological cancer cell lines and therefore,
preventing the cancer cell recovery following treatment with agents that cause
DNA damage, leading to increased cancer cell death. These results suggest that
such a combination treatment has the potential to result in improved clinical
outcomes compared to each agent alone:
* Selinexor treatment following exposure to DNA damaging agents such as
doxorubicin and idarubicin inhibited the repair mechanism of DNA damage
caused by these agents and resulted in synergistic Acute Myeloid Leukemia
(AML) cell killing as measured by induction of PARP and Caspase 3
cleavage.
* In vivo, low dose Selinexor (5 mg/kg) and radiation (3 Gy) decreased
xenograft tumor size of non-small cell lung cancer (A549 cell line) by 12%
and 30% relative to vehicle, respectively. In contrast, combination of
Selinexor and radiation resulted in an 86% tumor decrease.
In a poster presentation entitled "Quantification of Exportin-1 (XPO1)
Occupancy by Selective Inhibitor of Nuclear Export / SINE™ Compounds," data
demonstrated the development of a new pharmacodynamic assay that evaluate
direct binding of SINE to XPO1 by measuring XPO1 occupancy. This assay can be
used to correlate Selinexor dose, XPO1 binding and anti-tumor activity.
In a poster entitled "Identification of Novel Small Molecules as Selective
PAK4 Allosteric Modulators (PAMs) by Stable Isotope Labeling of Amino acids in
Cells (SILAC)", results of preclinical developmental studies with Karyopharm's
lead PAK4 allosteric modulators (PAMs) demonstrated anti-tumor activity both
in vitro and in vivo. These novel orally bioavailable small molecules showed
efficacy in both solid and hematological tumor xenograft models in mice with
minimal toxicity.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in